- Home
- MUE vs TIL Comparison
MUE vs TIL Comparison
Compare MUE & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUE
- TIL
- Stock Information
- Founded
- MUE 1999
- TIL 2018
- Country
- MUE United States
- TIL United States
- Employees
- MUE N/A
- TIL N/A
- Industry
- MUE Investment Bankers/Brokers/Service
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- MUE Finance
- TIL Health Care
- Exchange
- MUE Nasdaq
- TIL Nasdaq
- Market Cap
- MUE 219.4M
- TIL 177.1M
- IPO Year
- MUE N/A
- TIL 2021
- Fundamental
- Price
- MUE $10.01
- TIL $23.05
- Analyst Decision
- MUE
- TIL Buy
- Analyst Count
- MUE 0
- TIL 6
- Target Price
- MUE N/A
- TIL $120.50
- AVG Volume (30 Days)
- MUE 62.6K
- TIL 140.2K
- Earning Date
- MUE 01-01-0001
- TIL 11-12-2025
- Dividend Yield
- MUE 4.09%
- TIL N/A
- EPS Growth
- MUE N/A
- TIL N/A
- EPS
- MUE N/A
- TIL N/A
- Revenue
- MUE N/A
- TIL N/A
- Revenue This Year
- MUE N/A
- TIL N/A
- Revenue Next Year
- MUE N/A
- TIL N/A
- P/E Ratio
- MUE N/A
- TIL N/A
- Revenue Growth
- MUE N/A
- TIL N/A
- 52 Week Low
- MUE $8.53
- TIL $10.80
- 52 Week High
- MUE $10.17
- TIL $76.13
- Technical
- Relative Strength Index (RSI)
- MUE 75.47
- TIL 41.47
- Support Level
- MUE $9.37
- TIL $22.67
- Resistance Level
- MUE $10.08
- TIL $25.89
- Average True Range (ATR)
- MUE 0.08
- TIL 2.49
- MACD
- MUE 0.05
- TIL -0.51
- Stochastic Oscillator
- MUE 89.56
- TIL 3.40
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.